RxDoctor Payments DataLook up a doctor →

Ralph Goodman, MD

Endocrinology, Diabetes & Metabolism · Miramar Beach, FLNPI 1497718795

Payments from drug & device makers

$411,462in general payments, 2019–2025

Across 991 payments — averaging $415.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$407K
  • AbbVie$3K
  • Amgen$356
  • Radius Health, Inc.$267
  • Medtronic$194
  • Merck$171
  • plus $730 from 12 others

What the payments were for

  • Consulting fees$18,6565%
  • Speaking & faculty fees$341,71383%
  • Travel & lodging$39,0019%
  • Food & beverage$11,9223%
  • Education$1710%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$411,462 in reported general payments places this provider in the 90th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$19,189
Medicare patients
178
Services billed
282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide95$141,918
TrulicityDulaglutide76$109,700
JardianceEmpagliflozin63$85,825
TymlosAbaloparatide13$34,171
OzempicSemaglutide16$16,085
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$12,649
Humulin R U-500 KwikpenInsulin Regular, Human14$12,531
JanuviaSitagliptin Phosphate14$11,830
Lyumjev Kwikpen U-100Insulin Lispro-Aabc13$6,184
SynthroidLevothyroxine Sodium42$4,657
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$4,164
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic25$2,290
Levothyroxine Sodium199$2,193
LantusInsulin Glargine,hum.Rec.Anlog16$1,804
Nano 2nd Gen Pen NeedlePen Needle, Diabetic13$1,656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$407,058$251,618171 claims
Boehringer IngelheimJardiance$83$85,82563 claims
Radius Health, Inc.Tymlos$267$34,17113 claims
Novo NordiskOzempic$116$16,08516 claims
MerckJanuvia$171$11,83014 claims
AbbVieSynthroid$2,686$4,65742 claims
Sanofi-aventis U.S. LLCLantus$59$1,80416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Miramar Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →